The use of pectoral nerve block type II in patients undergoing trans-axillary thoracic outlet decompression.

Completed

• Conditions: pectoral minor syndrome; Thoracic inlet syndrome; 10041543

• Registration Number: NL-OMON49807
• Lead Sponsor: Catharina-ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 70

Inclusion Criteria

- Patients with NTOS
- Selected for a trans-axillary thoracic outlet decompression (TATOD) by the
TOS multidisciplinary workgroup.
- Fit for surgery, defined as ASA (American Society of Anesthesiologists)
Classification of I, II or III.
- 18 years of age or older
- Sufficient in speaking and writing the Dutch language
- Normal liver and renal function
- Informed consent

Exclusion Criteria

- Patients with a history of TOD (Redo-surgery)
- Patients with ATOS or VTOS
- ASA * 4
- Kidney or liver failure with contra-indication for NSAID or paracetamol
- Mental retardation
- Pregnancy
- Patients with chronic strong opioid use (>3 administrations per week or
continuous transdermal therapie, longer than the last 3 months)
- Allergy to one or more medications used in the study including,
ropivacaine, dexamethasone, propofol, sufentanil,
succinylcholine,
paracetamol, NSAID, morphine, granisetron

Study & Design

• Study Type: Interventional
• Study Design: Not specified